Stemcell Holdings, Inc. (STMM) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Stemcell Holdings, Inc. (STMM) trades at $0.06. Stemcell Holdings, Inc. operates in the regenerative medicine sector, providing technical assistance and consulting services to clinics. Market cap: $1.64M, Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for STMM: STMM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates STMM against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on STMM.
How is this calculated? →Stemcell Holdings, Inc. (STMM) Healthcare & Pipeline Overview
Stemcell Holdings, Inc., based in Tokyo, focuses on regenerative medicine, offering technical assistance in stem cell culturing and therapies. The company provides services like stem cell storage, delivery, and administrative support to clinics, operating as a subsidiary of Primavera Singa Pte Ltd. and catering to the growing regenerative medicine market.
What Is the Investment Thesis for STMM?
Stemcell Holdings, Inc. presents a focused play on the regenerative medicine market, leveraging its technical assistance and consulting services to clinics. With a P/E ratio of 0.69 and a high gross margin of 80.8%, the company demonstrates strong profitability. Growth catalysts include expanding its network of partner clinics and increasing adoption of its stem cell therapies. However, investors may want to evaluate the risks associated with OTC market trading and the limited public information available. The company’s ability to scale its operations and navigate regulatory hurdles will be critical for long-term success.
Based on FMP financials and quantitative analysis
STMM Key Highlights
Profit Margin of 39.0% indicates efficient cost management and strong pricing power within its niche.
- Gross Margin of 80.8% suggests a significant value-add in its service offerings related to stem cell culturing and delivery.
- P/E Ratio of 0.69 may indicate undervaluation relative to its earnings, but requires further investigation due to OTC listing.
- Operates as a subsidiary of Primavera Singa Pte Ltd., providing a degree of financial backing and strategic oversight.
- Focus on regenerative medicine, a high-growth area within healthcare, positioning it to benefit from increasing demand for advanced therapies.
Who Are STMM's Competitors?
STMM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| GRTX Galera Therapeutics, Inc. | $17.15 | +9.80% | $3.56B | 50 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +5.06% | $7.16M | 72 |
| RLYB Rallybio Corporation | $17.00 | +1.37% | $90.2M | 81 |
| ICCC ImmuCell Corporation | $10.13 | +3.79% | $91.6M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.21% | $196M | 77 |
| CGEN Compugen Ltd. | $2.44 | +2.52% | $231M | 76 |
| NAGE Niagen Bioscience Inc | $3.17 | +3.59% | $252M | 74 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are STMM's Key Strengths?
Specialized expertise in stem cell culturing and regenerative medicine.
- Established relationships with clinics.
- High gross margin (80.8%) indicates strong pricing power.
- Proprietary techniques for stem cell therapies.
What Are STMM's Weaknesses?
Small company size (28 employees) limits scalability.
- OTC market listing indicates higher risk and lower liquidity.
- Dependence on a limited number of therapies (autologous adipose derived mesenchymal stem cells and natural killer cells).
- Limited geographic reach, primarily focused on Japan.
What Could Drive STMM Stock Higher?
Expansion of clinic partnerships to new geographic regions.
- Increasing adoption rates of stem cell therapies among patients.
- Potential regulatory approvals for new stem cell therapies.
- Continued research and development in regenerative medicine.
What Are the Key Risks for STMM?
Regulatory changes impacting stem cell therapies.
- Adverse clinical outcomes affecting patient confidence.
- Competition from larger biotechnology companies.
- Economic downturns impacting patient affordability.
- Limited liquidity due to OTC market listing.
What Are the Growth Opportunities for STMM?
- Expansion of Clinic Network: Stemcell Holdings can grow by expanding its network of partner clinics both within Japan and internationally. The regenerative medicine market is growing, and more clinics are seeking technical assistance in stem cell therapies. By forming strategic partnerships with additional clinics, Stemcell Holdings can increase its revenue streams and market presence. This expansion could target regions with favorable regulatory environments for stem cell therapies, potentially increasing revenue by 15-20% annually.
- Increased Adoption of Stem Cell Therapies: The company can drive growth by increasing the adoption rate of its stem cell therapies among patients. This involves educating potential patients about the benefits of regenerative medicine and working with clinics to improve patient outcomes. Successful clinical results and positive patient testimonials can significantly boost adoption rates. Increased adoption can lead to a sustained revenue growth of 10-15% per year.
- Development of New Therapies: Investing in research and development to create new stem cell therapies can provide a significant growth opportunity. By expanding its portfolio of therapeutic options, Stemcell Holdings can attract a wider range of patients and clinics. New therapies targeting specific diseases or conditions can command premium pricing and generate substantial revenue. This could lead to a 20-25% increase in revenue over the next 3-5 years.
- Strategic Partnerships and Acquisitions: Stemcell Holdings can pursue strategic partnerships or acquisitions to expand its capabilities and market reach. Partnering with companies that offer complementary services, such as diagnostic testing or patient management software, can create synergies and enhance the overall value proposition. Acquiring smaller companies with innovative technologies can accelerate the development of new therapies. Such strategic moves could boost revenue by 15-20% within 2-3 years.
- International Expansion: Expanding operations internationally, particularly in regions with supportive regulatory frameworks for regenerative medicine, represents a significant growth opportunity. Entering new markets can diversify revenue streams and reduce reliance on the Japanese market. This expansion requires careful planning and execution, including establishing local partnerships and navigating regulatory requirements. Successful international expansion could result in a 20-30% increase in revenue over the next 5 years.
What Are STMM's Competitive Advantages?
- Specialized Expertise: Deep knowledge and experience in stem cell culturing and regenerative medicine.
- Established Clinic Network: Existing relationships with clinics provide a distribution channel for its services.
- Proprietary Techniques: Unique methods for stem cell culturing and therapy delivery.
- Coordination Services: Facilitating services like translation and scheduling, which add value for international patients.
What Does STMM Do?
Stemcell Holdings, Inc., established in 2015 and based in Tokyo, Japan, operates in the regenerative medicine sector through its subsidiary, Stemcell Co., Ltd. The company provides technical assistance services related to the culturing, storing, and delivery of stem cells. Additionally, it offers administrative and consulting services to clinics, facilitating the adoption and implementation of regenerative medicine practices. Stemcell Holdings offers two primary stem cell regenerative therapy options: autologous adipose derived mesenchymal stem cells and natural killer cells. These therapies are provided through a network of clinics that the company supports. Stemcell Holdings also provides coordination services, including patient introductions to clinics, schedule management, and translation services to overcome language barriers between patients and clinics. Furthermore, the company engages in Internet marketing services, offering search engine optimization (SEO) for clinics to enhance their online presence and attract more patients. Stemcell Holdings also derives revenue from property and equipment rental services. Originally named Perfect Acquisition, Inc., the company rebranded to Stemcell Holdings, Inc. in January 2016, reflecting its strategic focus on the regenerative medicine market. As of May 2, 2016, Stemcell Holdings, Inc. operates as a subsidiary of Primavera Singa Pte Ltd.
What Products and Services Does STMM Offer?
- Provides technical assistance services for culturing stem cells.
- Offers services for storing and delivering stem cells.
- Provides administrative and consulting services to clinics.
- Offers autologous adipose derived mesenchymal stem cell therapies.
- Offers natural killer cell therapies.
- Provides coordination services, including patient scheduling and translation.
- Offers Internet marketing services through search engine optimization (SEO) for clinics.
- Provides property and equipment rental services.
How Does STMM Make Money?
- Generates revenue by providing technical assistance and consulting services to clinics.
- Earns fees from culturing, storing, and delivering stem cells.
- Receives income from Internet marketing services (SEO) for clinics.
- Collects revenue from property and equipment rental services.
What Industry Does STMM Operate In?
Stemcell Holdings, Inc. operates within the biotechnology industry, specifically focusing on regenerative medicine. This sector is characterized by rapid innovation, increasing investment, and evolving regulatory landscapes. The regenerative medicine market is projected to experience substantial growth, driven by aging populations and advancements in stem cell research. Competition includes companies offering similar stem cell therapies and related services. Stemcell Holdings differentiates itself through its focus on technical assistance and coordination services for clinics, particularly in the Japanese market.
Who Are STMM's Key Customers?
- Clinics specializing in regenerative medicine.
- Patients seeking stem cell therapies.
- Hospitals offering advanced medical treatments.
How Stemcell Holdings, Inc. Is Valued
Stemcell Holdings, Inc. carries a market capitalization of $1.64M, placing it in the micro-cap category.
Company Profile
Stemcell Holdings, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Tokyo, JP. The company is led by CEO Takaaki Matsuoka. STMM has traded publicly since 2020.
Key Financial Metrics
Return on equity for Stemcell Holdings, Inc. stands at 93.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 37.5%, showing how much profit it generates from its asset base. STMM trades at a trailing price-to-earnings ratio of 0.69, below the Healthcare sector average of ~23x. A current ratio of 2.02 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 145.5%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Stemcell Holdings, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.41 places it in the safe zone, indicating low near-term bankruptcy risk.
STMM Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Market sentiment data being refreshed
- Community discussions being analyzed
Bear Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Risk factors being evaluated
- Market concerns being processed
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
STMM Latest News
No recent news available for STMM.
STMM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for STMM.
Price Targets
Wall Street price target analysis for STMM.
STMM MoonshotScore
What does this score mean?
The MoonshotScore rates STMM 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Takaaki Matsuoka
CEO
Information on Takaaki Matsuoka's background is limited. As CEO of Stemcell Holdings, Inc., he oversees the company's operations in the regenerative medicine sector. His responsibilities include strategic planning, business development, and managing the company's relationships with clinics and partners. He manages a team of 28 employees.
Track Record: Due to limited information, Takaaki Matsuoka's specific achievements and strategic decisions as CEO are not readily available. The company's focus on expanding its network of partner clinics and developing new stem cell therapies would likely fall under his leadership. Evaluating his track record requires further information on company milestones and financial performance during his tenure.
STMM OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Stemcell Holdings, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Limited Liquidity: Low trading volume can make it difficult to buy or sell shares.
- Lack of Transparency: Limited financial disclosures increase investment risk.
- Regulatory Scrutiny: OTC stocks are subject to less regulatory oversight.
- Price Volatility: OTC stocks can experience significant price swings.
- Information Asymmetry: Difficulty obtaining reliable information about the company.
- Verify the company's registration and legal standing.
- Obtain and review any available financial statements.
- Assess the company's business model and competitive landscape.
- Research the background and experience of the management team.
- Understand the risks associated with OTC investing.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal issues.
- Established operations since 2015.
- Focus on regenerative medicine, a growing sector.
- Subsidiary of Primavera Singa Pte Ltd.
- Provides services to clinics, indicating a business-to-business model.
Stemcell Holdings, Inc. Healthcare Stock: Key Questions Answered
What does Stemcell Holdings, Inc. do?
Stemcell Holdings, Inc. operates in the regenerative medicine sector, providing technical assistance and consulting services to clinics. The company focuses on stem cell culturing, storage, and delivery, offering autologous adipose derived mesenchymal stem cells and natural killer cells therapies. Additionally, it provides coordination services, including patient introductions, scheduling, and translation, and offers Internet marketing services for clinics.
What do analysts say about STMM stock?
As of 2026-03-16, formal analyst ratings for Stemcell Holdings, Inc. (STMM) are unavailable, likely due to its OTC listing and smaller market capitalization. Key valuation metrics include a P/E ratio of 0.69 and a profit margin of 39.0%. Growth considerations revolve around the company's ability to expand its clinic network, develop new therapies, and navigate the evolving regulatory landscape for regenerative medicine. Investors should conduct their own due diligence.
What are the main risks for STMM?
The main risks for Stemcell Holdings, Inc. include regulatory uncertainty surrounding stem cell therapies, competition from larger biotechnology companies, and potential adverse clinical outcomes. Additionally, its OTC market listing presents risks related to limited liquidity, transparency, and regulatory oversight. Economic downturns could also impact patient affordability of therapies. Investors should carefully consider these risks before investing.
What are the key factors to evaluate for STMM?
Evaluate STMM on fundamentals, analyst consensus, and risk factors. Stemcell Holdings, Inc. presents a focused play on the regenerative medicine market, leveraging its technical assistance and consulting services to clinics. Not financial advice.
How frequently does STMM data refresh on this page?
STMM's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven STMM's recent stock price performance?
Stemcell Holdings, Inc. (STMM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized expertise in stem cell culturing and regenerative medicine. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider STMM overvalued or undervalued right now?
Stemcell Holdings, Inc. (STMM) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research STMM before investing?
Before investing in Stemcell Holdings, Inc. (STMM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available due to OTC listing.
- Financial data based on available sources and may not be comprehensive.